ANDA 207504, held by Aurobindo Pharma. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 207504 (Aurovela 24 Fe), held by Aurobindo Pharma, was first approved by FDA on Jun 15, 2017, with 5 approved supplements and 0 published complete response letters.
Aurovela 24 Fe is indicated for use by women to prevent pregnancy. The efficacy of Aurovela 24 Fe in women with a body mass index (BMI) of greater than 35 kg/m 2 has not been evaluated.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 15, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aurovela 24 Fe0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Jul 14, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 14, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 28, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 28, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 15, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters